BN82451B + Placebo
Phase 2Terminated 0 watching 0 views this week⚡ Active
49
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Huntington's Disease
Conditions
Huntington's Disease
Trial Timeline
Sep 1, 2014 → Mar 31, 2016
NCT ID
NCT02231580About BN82451B + Placebo
BN82451B + Placebo is a phase 2 stage product being developed by Ipsen for Huntington's Disease. The current trial status is terminated. This product is registered under clinical trial identifier NCT02231580. Target conditions include Huntington's Disease.
Hype Score Breakdown
Clinical
17
Activity
12
Company
7
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02231580 | Phase 2 | Terminated |
Competing Products
15 competing products in Huntington's Disease
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| AFQ056 + Placebo | Novartis | Phase 2 | 52 |
| RO7234292 (RG6042) | Roche | Phase 2 | 52 |
| RG6496 + Placebo | Roche | Phase 1 | 33 |
| PF-02545920 + PF-02545920 | Pfizer | Phase 2 | 51 |
| 20 mg BID of PF-02545920 | Pfizer | Phase 2 | 51 |
| PF-02545920 + Placebo + PF-02545920 + Placebo | Pfizer | Phase 2 | 51 |
| ALN-HTT02 + Placebo | Alnylam Pharmaceuticals | Phase 1 | 30 |
| Tetrabenazine | Lundbeck | Approved | 82 |
| ISIS 443139 10 mg + ISIS 443139 30 mg + ISIS 443139 60 mg + ISIS 443139 90 mg + ISIS 443139 120 mg | Ionis Pharmaceuticals | Phase 1/2 | 38 |
| WVE-120102 + Placebo | WaVe Life Sciences | Phase 1/2 | 36 |
| WVE-120101 + Placebo | WaVe Life Sciences | Phase 1/2 | 36 |
| SAGE-718 | Supernus Pharmaceuticals | Phase 3 | 72 |
| SAGE-718 + Placebo | Supernus Pharmaceuticals | Phase 2 | 47 |
| OMS643762 + Placebo | Omeros Corporation | Phase 2 | 47 |
| VX15/2503 + Placebo | Vaccinex | Phase 2 | 44 |